nasal bpc 157 BPC157/TB500 Spray Bond Peptides BPC-157 + TB-500

Forscher untersuchen diese Kombination, da BPC-157 primaer ueber das NO-System und VEGFR2-Signalwege wirkt, waehrend TB-500 ueber die Aktin-Sequestrierung und das LKKTETQ-Motiv die Zellmigration beeinflusst

The April 2026 FDA action removes them from the Category 2 restricted compounding list effective April 23, 2026, and the FDAs Pharmacy Compounding Advisory Committee will review their compounding eligibility under 503A at its July 23-24, 2026 meeting

Contents: BPC-157 (Body Protection Compound), GHK-Cu (Copper Tripeptide-1), and TB-500 (Thymosin Beta-4 Fragment)

Mouse-study observations In the Billon 2023 and Billon 2024 studies, mice dosed at 25-50 mg/kg IP for up to 28 days showed no overt toxicity, no sickness-related weight loss, no liver-enzyme signal at the doses tested, and no cardiac dysfunction

Researchers investigate how selective NNMT inhibition affects cellular processes under controlled laboratory conditions